These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Moving Towards a Cure for MS: Increased Immunosuppression and Striving for No Evidence of Disease Activity (NEDA). Wong B; Cahill J; Rizvi S R I Med J (2013); 2018 Mar; 101(2):26-29. PubMed ID: 29490321 [TBL] [Abstract][Full Text] [Related]
23. Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis. Lucchetta RC; Leonart LP; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A Mult Scler Relat Disord; 2019 Oct; 35():7-15. PubMed ID: 31276913 [TBL] [Abstract][Full Text] [Related]
24. Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus. Deleu D; Canibaño B; Mesraoua B; Adeli G; Abdelmoneim MS; Ali Y; Elalamy O; Melikyan G; Boshra A Curr Med Res Opin; 2020 Feb; 36(2):251-260. PubMed ID: 31530036 [TBL] [Abstract][Full Text] [Related]
26. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R Curr Med Res Opin; 2018 Aug; 34(8):1419-1430. PubMed ID: 29583054 [TBL] [Abstract][Full Text] [Related]
27. Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis. van Eijndhoven E; Brauer M; Kee R; MacEwan J; Mucha L; Wong SL; Durand A; Shafrin J J Med Econ; 2020 May; 23(5):474-483. PubMed ID: 31903813 [No Abstract] [Full Text] [Related]
28. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. Montgomery SM; Kusel J; Nicholas R; Adlard N J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362 [TBL] [Abstract][Full Text] [Related]
29. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804 [TBL] [Abstract][Full Text] [Related]
30. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
31. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Thöne J; Gold R Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):365-70. PubMed ID: 21306281 [TBL] [Abstract][Full Text] [Related]
32. An update on cladribine for relapsing-remitting multiple sclerosis. Holmøy T; Torkildsen Ø; Myhr KM Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531 [TBL] [Abstract][Full Text] [Related]
33. Daclizumab for relapsing remitting multiple sclerosis. Liu J; Wang LN; Zhan S; Xia Y Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032 [TBL] [Abstract][Full Text] [Related]
34. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405 [TBL] [Abstract][Full Text] [Related]
35. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis]. Shmidt TE Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100 [TBL] [Abstract][Full Text] [Related]
36. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Morgan A; Tallantyre E; Ontaneda D Expert Rev Neurother; 2023 May; 23(5):433-444. PubMed ID: 37129299 [TBL] [Abstract][Full Text] [Related]
37. Dimethyl fumarate for relapsing-remitting multiple sclerosis. Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591 [TBL] [Abstract][Full Text] [Related]
38. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis. Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909 [TBL] [Abstract][Full Text] [Related]
39. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Burt RK; Tappenden P; Han X; Quigley K; Arnautovic I; Sharrack B; Snowden JA; Hartung D Mult Scler Relat Disord; 2020 Oct; 45():102404. PubMed ID: 32731201 [TBL] [Abstract][Full Text] [Related]
40. Oral agents in multiple sclerosis. Lorefice L; Fenu G; Frau J; Coghe GC; Marrosu MG; Cocco E Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):15-25. PubMed ID: 25924620 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]